WAY
Get informed when a big investor buys or sells
+ FollowUndervalued by 166.9% based on the discounted cash flow analysis.
| Market cap | $4.30 Billion |
|---|---|
| Enterprise Value | $4.36 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.63 |
| Beta | 0.07 |
| Outstanding Shares | 191,666,913 |
| P/E Ratio | 32.04 |
|---|---|
| PEG | 66.92 |
| Price to Sales | 3.74 |
| Price to Book Ratio | 1.12 |
| Enterprise Value to Revenue | 3.77 |
| Enterprise Value to EBIT | 17.81 |
| Enterprise Value to Net Income | 34 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2338▼ 36.13% |
|---|---|
| Total Calls | 523,000▲ 57.53% |
| Total Puts | 645,300▲ 21.85% |
Holdings and activity of institutional investors.
| Ownership % | 106.78%▲ 2.62% |
|---|---|
| Total Invested | $4.93B▼ 24.51% |
| Investors Holding | 320▲ 8.00% |
No data
This is the most critical committee for Waystar as it oversees Medicare and Medicaid, the primary drivers of the healthcare reimbursement ecosystem that Waystar facilitates.
The committee controls the actual cash flow to HHS and CMS, directly influencing the liquidity and spending power of the healthcare providers who pay for Waystar's services.
This committee directly regulates the healthcare industry and the Department of Health and Human Services, impacting the standards and legal environment for healthcare payments.